Stocks and Investing
Stocks and Investing
Thu, January 28, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Larry Biegelsen Maintained (ABT) at Buy with Increased Target to $137 on, Jan 28th, 2021
Larry Biegelsen of Wells Fargo, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $128 to $137 on, Jan 28th, 2021.
Larry has made no other calls on ABT in the last 4 months.
There are 3 other peers that have a rating on ABT. Out of the 3 peers that are also analyzing ABT, 0 agree with Larry's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Larry
- Matthew Taylor of "UBS" Maintained at Strong Buy with Increased Target to $122 on, Thursday, October 22nd, 2020
- Rick Wise of "Stifel" Maintained at Strong Buy with Increased Target to $120 on, Wednesday, October 21st, 2020
- Robbie Marcus of "JP Morgan" Maintained at Buy with Increased Target to $125 on, Friday, October 9th, 2020
Contributing Sources